Clearside Biomedical, Inc. CLSDQ
0.25
0.00
0.00%
as of 22 Jul
- Market cap
- $2.2M
- P/E
- 0.0×
Follow CLSDQ
| Older periods | Dec '24 | Mar '25 | Jun '25 | Sep '25 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
125.45% | 91.00% | 71.96% | 58.59% | |
| (116.16%) | (103.03%) | (112.50%) | (127.43%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(174.33%) | (218.51%) | (234.80%) | (307.11%) | |
Average Days of Receivables |
111.21 | 149.14 | 71.49 | 29.16 | |
Free Cash Flow per Share |
(5.22) | (4.60) | (4.28) | (4.15) | |
Free Cash Flow |
(25.67) | (23.61) | (22.23) | (21.75) | |
Capital Expenditures |
(0.98) | (0.93) | (0.51) | (0.45) | |
Piotroski F-Score |
3.00 | 1.00 | 1.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
131.13% | 70.25% | 55.20% | 45.16% | |
Accounts Receivable Turnover |
4.37 | 3.11 | 6.49 | 6.32 | |
Accounts Payable Turnover |
0.00 | 0.37 | 0.00 | 0.00 | |
Inventory Turnover |
— | 0.00 | — | — | |
Average Days of Payables |
0.00 | 1,158.56 | 0.00 | 0.00 | |
Days of Inventory on Hand |
— | 0.00 | — | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,117.19% | 463.28% | 346.11% | 397.24% | |
Selling, General and Administrative Expense of Revenue |
709.56% | 313.68% | 268.99% | 380.59% | |
Share Based Compensation of Revenue |
271.21% | 110.84% | 89.92% | 99.94% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.72 | 0.74 | 0.78 | 0.82 | |
Depreciation/Fixed assets |
(0.03) | (0.02) | 0.03 | 0.09 | |
Capex/Depreciation |
8.65 | 16.59 | (5.44) | (1.62) | |
Revenue per Share |
0.34 | 0.73 | 0.80 | 0.64 | |
Operating CF per Share |
(5.02) | (4.42) | (4.18) | (4.07) | |
Capex per Share |
(0.20) | (0.18) | (0.10) | (0.09) | |
Capex to Sales |
0.59 | 0.25 | 0.12 | 0.14 | |
Net Profit Margin |
(2,064.42%) | (818.60%) | (665.22%) | (780.93%) |
Columns are period end dates